- Home
- MSC vs MOLN Comparison
MSC vs MOLN Comparison
Compare MSC & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MSC | MOLN |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | Hong Kong | Switzerland |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.9M | 170.5M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MSC | MOLN |
|---|---|---|
| Price | $0.96 | $3.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | ★ 185.8K | 1.7K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $450.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $3.53 |
| 52 Week High | $4.69 | $5.36 |
Technical Indicators
Market Signals| Indicator | MSC | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 40.65 |
| Support Level | $0.77 | N/A |
| Resistance Level | $1.11 | $4.21 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 61.78 | 0.00 |
Price Performance
Historical ComparisonAbout MSC Studio City International Holdings Limited
Studio City International Holdings Ltd is a gaming, retail, and entertainment resort located in Cotai, Macau. It operates Studio City Casino with around 250 mass-market gaming tables; including tables for VIP rolling chip operations, and 552 gaming machines. Studio City features luxury hotel rooms, diverse food and beverage establishments, and complementary retail space. In addition, the company offers non-gaming attractions, including the world's first figure-8 Ferris wheel, a deluxe nightclub and karaoke venue, a live performance arena, an outdoor and an indoor water park. Geographically, the company derives the majority of its revenue from the Macau region.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.